Avalon Pharmaceuticals (AVRX) Receives Audit Committee Opinion Containing Going Concern Statement
More News related to AVRX
- Avalon Pharmaceuticals (AVRX) Common Stock to be Suspended From Trading
- Clinical Data (CLDA) and Avalon Pharmaceuticals (AVRX) To Merge
- Cantor Fitzgerald Downgrades Avalon Pharmaceuticals (AVRX) to Hold
- Avalon Pharmaceuticals (AVRX) Reports Q1 Loss of $0.37, Misses By 7c
- Avalon Pharmaceuticals (AVRX) Receives Audit Committee Opinion Containing Going Concern Statement
Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX) today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 contained an unqualified audit opinion from its independent public accounting firm, Ernst & Young LLP, which included a "going concern" explanatory statement.
Avalon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics using AvalonRx technology in the United States. [BCS]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
